Targeting protein aggregation for the treatment of degenerative diseases

[1]  R. E. Bendel,et al.  Observational report , 2017, Medicine.

[2]  E. Siemers,et al.  Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years , 2015, Alzheimer's & dementia.

[3]  E. Masliah,et al.  Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease , 2015, Neurobiology of Disease.

[4]  Lisa M. Ryno,et al.  Unfolded protein response‐induced ERdj3 secretion links ER stress to extracellular proteostasis , 2015, The EMBO journal.

[5]  B. de Strooper,et al.  Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. , 2015, Annual review of pharmacology and toxicology.

[6]  M. Benson,et al.  Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[7]  Arun K. Ghosh,et al.  BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease. , 2014, Chemical Society reviews.

[8]  P. McLean,et al.  α-Synuclein Multimers Cluster Synaptic Vesicles and Attenuate Recycling , 2014, Current Biology.

[9]  T. Südhof,et al.  α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation , 2014, Proceedings of the National Academy of Sciences.

[10]  L. Lannfelt,et al.  Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice , 2014, Neurobiology of Disease.

[11]  Lisa M. Ryno,et al.  Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain , 2014, Proceedings of the National Academy of Sciences.

[12]  T. Coelho,et al.  CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  M. Staufenbiel,et al.  Multiple Factors Contribute to the Peripheral Induction of Cerebral β-Amyloidosis , 2014, The Journal of Neuroscience.

[14]  S. Prusiner,et al.  Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice , 2014, Proceedings of the National Academy of Sciences.

[15]  S. Prusiner,et al.  Serial propagation of distinct strains of Aβ prions from Alzheimer’s disease patients , 2014, Proceedings of the National Academy of Sciences.

[16]  Y. Nishiyama,et al.  Metal-dependent amyloid β-degrading catalytic antibody construct. , 2014, Journal of biotechnology.

[17]  L. Grinberg,et al.  Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies , 2014, Neuron.

[18]  D. Otzen,et al.  How Epigallocatechin Gallate Can Inhibit α-Synuclein Oligomer Toxicity in Vitro♦ , 2014, The Journal of Biological Chemistry.

[19]  L. Iyer,et al.  One siRNA pool targeting the λ constant region stops λ light-chain production and causes terminal endoplasmic reticulum stress. , 2014, Blood.

[20]  V. Buchman,et al.  Multistep process of FUS aggregation in the cell cytoplasm involves RNA-dependent and RNA-independent mechanisms , 2014, Human molecular genetics.

[21]  Huanxiang Liu,et al.  Exploring the Influence of EGCG on the β-Sheet-Rich Oligomers of Human Islet Amyloid Polypeptide (hIAPP1–37) and Identifying Its Possible Binding Sites from Molecular Dynamics Simulation , 2014, PloS one.

[22]  J. Shorter,et al.  Reversing deleterious protein aggregation with re-engineered protein disaggregases , 2014, Cell cycle.

[23]  Kenji Watanabe,et al.  Physiological IgM Class Catalytic Antibodies Selective for Transthyretin Amyloid* , 2014, The Journal of Biological Chemistry.

[24]  U. Sengupta,et al.  Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles , 2014, The Journal of Neuroscience.

[25]  M. Maurer,et al.  Quantification of Transthyretin Kinetic Stability in Human Plasma Using Subunit Exchange , 2014, Biochemistry.

[26]  R. Vassar,et al.  Targeting the β secretase BACE1 for Alzheimer's disease therapy , 2014, The Lancet Neurology.

[27]  Zeshan Ahmed,et al.  A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity , 2014, Acta Neuropathologica.

[28]  C. Soto,et al.  Aggregate-Depleted Brain Fails to Induce Aβ Deposition in a Mouse Model of Alzheimer's Disease , 2014, PloS one.

[29]  D. Seldin,et al.  Immunoglobulin light chain amyloidosis , 2014, Expert review of hematology.

[30]  S. Radford,et al.  Ion Mobility Spectrometry–Mass Spectrometry Defines the Oligomeric Intermediates in Amylin Amyloid Formation and the Mode of Action of Inhibitors , 2013, Journal of the American Chemical Society.

[31]  K. Caldwell,et al.  Potentiated Hsp104 Variants Antagonize Diverse Proteotoxic Misfolding Events , 2013, Cell.

[32]  H. True,et al.  Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones. , 2014, Human molecular genetics.

[33]  E. Nordh,et al.  Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. , 2013, JAMA.

[34]  M. Goedert,et al.  Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice , 2013, Acta Neuropathologica.

[35]  D. Holtzman,et al.  Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.

[36]  T. Golde,et al.  γ-Secretase inhibitors and modulators. , 2013, Biochimica et biophysica acta.

[37]  G. Bitan,et al.  Modulators of amyloid protein aggregation and toxicity: EGCG and CLR01 , 2013 .

[38]  K. Nilsson,et al.  Seeded strain‐like transmission of β‐amyloid morphotypes in APP transgenic mice , 2013, EMBO reports.

[39]  B. Meier,et al.  Structural and functional characterization of two alpha-synuclein strains , 2013, Nature Communications.

[40]  Mathias Jucker,et al.  Self-propagation of pathogenic protein aggregates in neurodegenerative diseases , 2013, Nature.

[41]  T. Uzu,et al.  Altered unfolded protein response is implicated in the age-related exacerbation of proteinuria-induced proximal tubular cell damage. , 2013, The American journal of pathology.

[42]  J. Rogers,et al.  Allosteric Heat Shock Protein 70 Inhibitors Rapidly Rescue Synaptic Plasticity Deficits by Reducing Aberrant Tau , 2013, Biological Psychiatry.

[43]  B. Bettencourt,et al.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis. , 2013, The New England journal of medicine.

[44]  Huaiyi Yang,et al.  De novo generation of infectious prions with bacterially expressed recombinant prion protein , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  Teresa Coelho,et al.  Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy , 2013, Journal of Neurology.

[46]  H. Paulson,et al.  The E3 ubiquitin ligase CHIP and the molecular chaperone Hsc70 form a dynamic, tethered complex. , 2013, Biochemistry.

[47]  M. Farlow,et al.  Immunotherapy for Alzheimer's disease. , 2013, Neurologic clinics.

[48]  R. Nixon,et al.  The role of autophagy in neurodegenerative disease , 2013, Nature Medicine.

[49]  F. Brodsky,et al.  Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds , 2013, Proceedings of the National Academy of Sciences.

[50]  Barbara Calamini,et al.  Heat Shock Response Activation Exacerbates Inclusion Body Formation in a Cellular Model of Huntington Disease* , 2013, The Journal of Biological Chemistry.

[51]  Bin Zhang,et al.  Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons , 2013, Cell.

[52]  J. Brodsky,et al.  Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. , 2013, ACS chemical neuroscience.

[53]  B. Nordestgaard,et al.  Genetic Stabilization of Transthyretin, Cerebrovascular Disease, and Life Expectancy , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[54]  J. Kelly,et al.  Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. , 2013, Journal of the American Chemical Society.

[55]  Lisa M. Ryno,et al.  Broadly applicable methodology for the rapid and dosable small molecule-mediated regulation of transcription factors in human cells. , 2013, Journal of the American Chemical Society.

[56]  B. Ghetti,et al.  Brain homogenates from human tauopathies induce tau inclusions in mouse brain , 2013, Proceedings of the National Academy of Sciences.

[57]  Yvonne S. Eisele,et al.  From Soluble Aβ to Progressive Aβ Aggregation: Could Prion‐Like Templated Misfolding Play a Role? , 2013, Brain pathology.

[58]  Lisa M. Ryno,et al.  Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. , 2013, Cell reports.

[59]  Anjanabha Saha,et al.  Inhibition of Usp14 Stimulates the Proteolytic Degradation and Clearance of Misfolded Proteins Associated with Neurodegenerative Diseases , 2013 .

[60]  V. Uversky,et al.  Imbalance of Hsp70 family variants fosters tau accumulation , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  J. Trojanowski,et al.  Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. , 2013, JAMA neurology.

[62]  Virginia M. Y. Lee,et al.  Neurofibrillary tangle‐like tau pathology induced by synthetic tau fibrils in primary neurons over‐expressing mutant tau , 2013, FEBS letters.

[63]  O. Dewit,et al.  Control of AA amyloidosis complicating Crohn's disease: a clinico‐pathological study , 2013, European Journal of Clinical Investigation.

[64]  J. Brender,et al.  Insights into antiamyloidogenic properties of the green tea extract (−)-epigallocatechin-3-gallate toward metal-associated amyloid-β species , 2013, Proceedings of the National Academy of Sciences.

[65]  Carl Frieden,et al.  Quantitative analysis of the time course of Aβ oligomerization and subsequent growth steps using tetramethylrhodamine-labeled Aβ , 2013, Proceedings of the National Academy of Sciences.

[66]  M. Lubberink,et al.  In Vivo Visualization of Amyloid Deposits in the Heart with 11C-PIB and PET , 2013, The Journal of Nuclear Medicine.

[67]  D. Housman,et al.  Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease , 2013, Proceedings of the National Academy of Sciences.

[68]  J. Trojanowski,et al.  Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy , 2013, The Journal of Neuroscience.

[69]  Catherine A. Collins,et al.  Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation , 2012, Nature chemical biology.

[70]  James Rooney,et al.  A heavy heart. , 2012, American journal of respiratory and critical care medicine.

[71]  R. Kane,et al.  Pathogenic Serum Amyloid A 1.1 Shows a Long Oligomer-rich Fibrillation Lag Phase Contrary to the Highly Amyloidogenic Non-pathogenic SAA2.2* , 2012, The Journal of Biological Chemistry.

[72]  J. Trojanowski,et al.  Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.

[73]  G. Merlini,et al.  Amyloidosis in autoinflammatory syndromes. , 2012, Autoimmunity reviews.

[74]  E. Masliah,et al.  Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission , 2012, The Journal of Neuroscience.

[75]  Martin L. Duennwald,et al.  Pharmacological tuning of heat shock protein 70 modulates polyglutamine toxicity and aggregation. , 2012, ACS chemical biology.

[76]  E. Morignat,et al.  Prion-like acceleration of a synucleinopathy in a transgenic mouse model , 2012, Neurobiology of Aging.

[77]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[78]  R. Labaudinière,et al.  Tafamidis for transthyretin familial amyloid polyneuropathy , 2012, Neurology.

[79]  Steven M. Johnson,et al.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. , 2012, Journal of molecular biology.

[80]  B. Bukau,et al.  Chaperone networks in protein disaggregation and prion propagation. , 2012, Journal of structural biology.

[81]  W. Klein,et al.  Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease , 2012, Neurobiology of Aging.

[82]  I. Narita,et al.  Treatment with Biologic Agents Improves the Prognosis of Patients with Rheumatoid Arthritis and Amyloidosis , 2012, The Journal of Rheumatology.

[83]  S. Prusiner,et al.  A Unifying Role for Prions in Neurodegenerative Diseases , 2012, Science.

[84]  Stephen J. DeArmond,et al.  Purified and synthetic Alzheimer’s amyloid beta (Aβ) prions , 2012, Proceedings of the National Academy of Sciences.

[85]  R. Labaudinière,et al.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade , 2012, Proceedings of the National Academy of Sciences.

[86]  E. Wanker,et al.  Green tea halts progression of cardiac transthyretin amyloidosis: an observational report , 2012, Clinical Research in Cardiology.

[87]  D. Cleveland,et al.  Prion-like spread of protein aggregates in neurodegeneration , 2012, The Journal of experimental medicine.

[88]  J. Trojanowski,et al.  Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice , 2012, The Journal of experimental medicine.

[89]  K. Dharmarajan,et al.  Transthyretin Cardiac Amyloidoses in Older North Americans , 2012, Journal of the American Geriatrics Society.

[90]  D. Holtzman,et al.  Trans-cellular Propagation of Tau Aggregation by Fibrillar Species* , 2012, The Journal of Biological Chemistry.

[91]  Efstathios D. Gennatas,et al.  Predicting Regional Neurodegeneration from the Healthy Brain Functional Connectome , 2012, Neuron.

[92]  D. Raleigh,et al.  Analysis of the inhibition and remodeling of islet amyloid polypeptide amyloid fibers by flavanols. , 2012, Biochemistry.

[93]  Mathias Jucker,et al.  The Amyloid State of Proteins in Human Diseases , 2012, Cell.

[94]  David Eisenberg,et al.  Atomic View of a Toxic Amyloid Small Oligomer , 2012, Science.

[95]  H. Jono,et al.  Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy , 2012, Neurology.

[96]  B. de Strooper,et al.  Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. , 2012, Cold Spring Harbor perspectives in medicine.

[97]  Monica A. Chalfant,et al.  Small Molecule Proteostasis Regulators for Protein Conformational Diseases , 2011, Nature chemical biology.

[98]  Bruce L. Miller,et al.  Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.

[99]  M. Staufenbiel,et al.  Soluble Aβ Seeds Are Potent Inducers of Cerebral β-Amyloid Deposition , 2011, The Journal of Neuroscience.

[100]  D. Garza,et al.  Firefly luciferase mutants as sensors of proteome stress , 2011, Nature Methods.

[101]  R. Falk,et al.  Cardiac Amyloidosis: A Treatable Disease, Often Overlooked , 2011, Circulation.

[102]  P. Davies,et al.  Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models , 2011, The Journal of Biological Chemistry.

[103]  M. Kabani,et al.  Hsc70 Protein Interaction with Soluble and Fibrillar α-Synuclein* , 2011, The Journal of Biological Chemistry.

[104]  D. Selkoe,et al.  α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation , 2011, Nature.

[105]  Andreas Bracher,et al.  Molecular chaperones in protein folding and proteostasis , 2011, Nature.

[106]  J. Kelly,et al.  Amyloid-β Forms Fibrils by Nucleated Conformational Conversion of Oligomers , 2011, Nature chemical biology.

[107]  B. Ericzon,et al.  Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR) , 2011, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[108]  N. Greig,et al.  Targets for AD treatment: conflicting messages from γ‐secretase inhibitors , 2011, Journal of neurochemistry.

[109]  E. Masliah,et al.  Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease , 2011, PloS one.

[110]  J. Morris,et al.  Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.

[111]  D. Ron,et al.  Selective Inhibition of a Regulatory Subunit of Protein Phosphatase 1 Restores Proteostasis , 2011, Science.

[112]  D. Seldin,et al.  Preclinical Development of siRNA Therapeutics for AL Amyloidosis , 2011, Gene Therapy.

[113]  Fred H. Gage,et al.  In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.

[114]  M. Gertz.  Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk‐stratification, and management , 2011, American journal of hematology.

[115]  Michele Vendruscolo,et al.  Amyloid-like Aggregates Sequester Numerous Metastable Proteins with Essential Cellular Functions , 2011, Cell.

[116]  P. Aridon,et al.  Protective Role of Heat Shock Proteins in Parkinson’s Disease , 2011, Neurodegenerative Diseases.

[117]  B. Hyman,et al.  Heat‐shock protein 70 modulates toxic extracellular α‐synuclein oligomers and rescues trans‐synaptic toxicity , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[118]  Yvonne S. Eisele,et al.  The presence of Aβ seeds, and not age per se, is critical to the initiation of Aβ deposition in the brain , 2011, Acta Neuropathologica.

[119]  Michael R. Schmidt,et al.  Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils. , 2011, Nature chemical biology.

[120]  L. Petrucelli,et al.  Targeting heat shock proteins in tauopathies. , 2010, Current Alzheimer research.

[121]  Frank Baumann,et al.  Peripherally Applied Aβ-Containing Inoculates Induce Cerebral β-Amyloidosis , 2010, Science.

[122]  Fanling Meng,et al.  The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. , 2010, Biochemistry.

[123]  M. Wolfe.  Structure, mechanism and inhibition of γ-secretase and presenilin-like proteases , 2010, Biological chemistry.

[124]  Andrey Alexeyenko,et al.  Genome-wide pathway analysis implicates intracellular transmembrane protein transport in Alzheimer disease , 2010, Journal of Human Genetics.

[125]  Simon Watkins,et al.  An Autophagy-Enhancing Drug Promotes Degradation of Mutant α1-Antitrypsin Z and Reduces Hepatic Fibrosis , 2010, Science.

[126]  F. Salvi,et al.  Transthyretin-related amyloidoses and the heart: a clinical overview , 2010, Nature Reviews Cardiology.

[127]  Min Jae Lee,et al.  Enhancement of Proteasome Activity by a Small-Molecule Inhibitor of Usp14 , 2010, Nature.

[128]  M. Benson,et al.  Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment , 2010, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[129]  C. Mathias,et al.  Hereditary fibrinogen A alpha-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. , 2010, Blood.

[130]  D. Ehrnhoefer,et al.  EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity , 2010, Proceedings of the National Academy of Sciences.

[131]  Matthias Mueller,et al.  The HSP70 Molecular Chaperone Is Not Beneficial in a Mouse Model of α-synucleinopathy , 2010, PloS one.

[132]  Fei Wang,et al.  Generating a Prion with Bacterially Expressed Recombinant Prion Protein , 2010, Science.

[133]  M. Dimopoulos,et al.  Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  R. Falk,et al.  Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38α MAPK pathway , 2010, Proceedings of the National Academy of Sciences.

[135]  Steven M. Johnson,et al.  Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. , 2010, Current opinion in structural biology.

[136]  B. Strooper,et al.  The secretases: enzymes with therapeutic potential in Alzheimer disease , 2010, Nature Reviews Neurology.

[137]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[138]  H. Erdem,et al.  No regression of renal amyloid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy. , 2010, Journal of nephrology.

[139]  S. Ikeda,et al.  A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept , 2011, Rheumatology International.

[140]  Lawrence Rajendran,et al.  The Transcellular Spread of Cytosolic Amyloids, Prions, and Prionoids , 2009, Neuron.

[141]  E. Gavilan,et al.  Dysfunction of the unfolded protein response increases neurodegeneration in aged rat hippocampus following proteasome inhibition , 2009, Aging cell.

[142]  Elizabeth A Miller,et al.  Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging , 2009, Proceedings of the National Academy of Sciences.

[143]  A. Aguzzi,et al.  Induction of cerebral β-amyloidosis: Intracerebral versus systemic Aβ inoculation , 2009, Proceedings of the National Academy of Sciences.

[144]  J. Kelly,et al.  Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins , 2009, Proceedings of the National Academy of Sciences.

[145]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[146]  R. Morimoto,et al.  Biological and chemical approaches to diseases of proteostasis deficiency. , 2009, Annual review of biochemistry.

[147]  M. Diamond,et al.  Propagation of Tau Misfolding from the Outside to the Inside of a Cell* , 2009, Journal of Biological Chemistry.

[148]  M. Wolfe.  Tau Mutations in Neurodegenerative Diseases* , 2009, Journal of Biological Chemistry.

[149]  L. Mucke,et al.  Neprilysin Overexpression Inhibits Plaque Formation But Fails to Reduce Pathogenic Aβ Oligomers and Associated Cognitive Deficits in Human Amyloid Precursor Protein Transgenic Mice , 2009, The Journal of Neuroscience.

[150]  R. Kopito,et al.  Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates , 2009, Nature Cell Biology.

[151]  S. Wickner,et al.  Hsp104 and ClpB: protein disaggregating machines. , 2009, Trends in biochemical sciences.

[152]  P. Westermark,et al.  Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis , 2008, The Journal of pathology.

[153]  John R. Yates,et al.  Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases , 2008, Cell.

[154]  J. Keats,et al.  Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. , 2008, Blood.

[155]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[156]  J. Kelly,et al.  Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. , 2008, Biochemistry.

[157]  D. Ehrnhoefer,et al.  EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers , 2008, Nature Structural &Molecular Biology.

[158]  F. Gejyo,et al.  A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab , 2008, Rheumatology International.

[159]  A. Korczyn.  The amyloid cascade hypothesis , 2008, Alzheimer's & Dementia.

[160]  Richard I. Morimoto,et al.  Adapting Proteostasis for Disease Intervention , 2008, Science.

[161]  John Collinge,et al.  A General Model of Prion Strains and Their Pathogenicity , 2007, Science.

[162]  K. Sarge,et al.  Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response , 2007, Journal of Molecular Medicine.

[163]  M. Dimopoulos,et al.  Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone , 2007, Haematologica.

[164]  G. Merlini,et al.  Bortezomib in the treatment of AL amyloidosis: targeted therapy? , 2007, Haematologica.

[165]  L. Mucke,et al.  Accelerating Amyloid-β Fibrillization Reduces Oligomer Levels and Functional Deficits in Alzheimer Disease Mouse Models* , 2007, Journal of Biological Chemistry.

[166]  B. Hazenberg,et al.  Beneficial effect of eprodisate (NC-503) on the preservation of kidney function in AA amyloidosis patients : 3-year follow-up results , 2007 .

[167]  M. Tsukano,et al.  Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. , 2007, Clinical and experimental rheumatology.

[168]  A. Aguzzi,et al.  Insights into prion strains and neurotoxicity , 2007, Nature Reviews Molecular Cell Biology.

[169]  P. Walter,et al.  Signal integration in the endoplasmic reticulum unfolded protein response , 2007, Nature Reviews Molecular Cell Biology.

[170]  D. Selkoe,et al.  Aβ Oligomers – a decade of discovery , 2007, Journal of neurochemistry.

[171]  E. Wanker,et al.  Small Molecule Inducers of Heat-Shock Response Reduce polyQ-Mediated Huntingtin Aggregation , 2007, Neurodegenerative Diseases.

[172]  C. Rowe,et al.  Imaging β-amyloid burden in aging and dementia , 2007, Neurology.

[173]  P. Greengard,et al.  The Arctic Alzheimer mutation favors intracellular amyloid‐β production by making amyloid precursor protein less available to α‐secretase , 2007, Journal of neurochemistry.

[174]  R. Comenzo.  Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis. , 2007, Contributions to nephrology.

[175]  I. Lott,et al.  Alzheimer's disease in Down syndrome: neurobiology and risk. , 2007, Mental retardation and developmental disabilities research reviews.

[176]  Yoshiki Sekijima,et al.  Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis , 2006, Neuroscience Research.

[177]  V. Trinkaus-Randall,et al.  Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts. , 2006, The American journal of pathology.

[178]  I. Ferrer,et al.  A&bgr; Species Removal After A&bgr;42 Immunization , 2006, Journal of neuropathology and experimental neurology.

[179]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[180]  D. Walsh,et al.  Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host , 2006, Science.

[181]  Ehud Cohen,et al.  Opposing Activities Protect Against Age-Onset Proteotoxicity , 2006, Science.

[182]  P. Merlet,et al.  Impact of Liver Transplantation on Cardiac Autonomic Denervation in Familial Amyloid Polyneuropathy , 2006, Medicine.

[183]  E. Powers,et al.  The kinetics of nucleated polymerizations at high concentrations: amyloid fibril formation near and above the "supercritical concentration". , 2006, Biophysical journal.

[184]  L. Raymond,et al.  Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin , 2006, Cell.

[185]  K. Sleegers,et al.  Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. , 2006, American journal of human genetics.

[186]  G. Merlini,et al.  Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. , 2006, Blood.

[187]  M. Benson,et al.  Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides , 2006, Muscle & nerve.

[188]  J. Kelly,et al.  Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis , 2006, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[189]  P. Bross,et al.  Reduced heat shock response in human mononuclear cells during aging and its association with polymorphisms in HSP70 genes , 2006, Cell stress & chaperones.

[190]  Steven M. Johnson,et al.  Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. , 2005, Accounts of chemical research.

[191]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[192]  R. Falk,et al.  Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. , 2005, Archives of internal medicine.

[193]  Makoto Hashimoto,et al.  Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.

[194]  J. Kelly,et al.  The Biological and Chemical Basis for Tissue-Selective Amyloid Disease , 2005, Cell.

[195]  H. Dyson,et al.  Intrinsically unstructured proteins and their functions , 2005, Nature Reviews Molecular Cell Biology.

[196]  R. Tanzi,et al.  Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.

[197]  E. Masliah,et al.  Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease , 2005, Neurology.

[198]  R. Kaufman,et al.  The mammalian unfolded protein response. , 2003, Annual review of biochemistry.

[199]  R. Fletterick,et al.  Conversion of a-helices into ,f-sheets features in the formation of the scrapie prion proteins , 2005 .

[200]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[201]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[202]  D. Schenk.  Hopes remain for an Alzheimer's vaccine , 2004, Nature.

[203]  Joleen T White,et al.  Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. , 2004, Biochemistry.

[204]  B. Ericzon,et al.  Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidotic polyneuropathy world transplant registry , 2004, Transplantation.

[205]  M. Ohno,et al.  BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's Disease , 2004, Neuron.

[206]  R. Morimoto,et al.  Regulation of longevity in Caenorhabditis elegans by heat shock factor and molecular chaperones. , 2003, Molecular biology of the cell.

[207]  D. Selkoe,et al.  Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.

[208]  C. Dobson.  Protein folding and misfolding , 2003, Nature.

[209]  P. Lansbury,et al.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. , 2003, Annual review of neuroscience.

[210]  M. Tsukano,et al.  Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis , 2003, Clinical Rheumatology.

[211]  H. Mori,et al.  Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form but also the pathological oligomeric form , 2003, Neuroscience Letters.

[212]  O. Suhr.  Impact of liver transplantation on familial amyloidotic polyneuropathy (FAP) patients' symptoms and complications , 2003, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[213]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[214]  M. Pepys,et al.  Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy , 2003, British journal of haematology.

[215]  J. Sacchettini,et al.  Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. , 2003, Angewandte Chemie.

[216]  J. Morrison,et al.  Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease , 2003, Neurology.

[217]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[218]  J. Kelly,et al.  Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics , 2003, Science.

[219]  J. Kelly,et al.  Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[220]  R. Wetzel,et al.  Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. , 2002, Human Molecular Genetics.

[221]  D. Schenk.  Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning , 2002, Nature Reviews Neuroscience.

[222]  Christopher A Ross,et al.  Polyglutamine Pathogenesis Emergence of Unifying Mechanisms for Huntington's Disease and Related Disorders , 2002, Neuron.

[223]  Ronald Wetzel,et al.  Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[224]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[225]  P. Lansbury,et al.  Neurodegenerative disease: Amyloid pores from pathogenic mutations , 2002, Nature.

[226]  Sofia Nyström,et al.  Transmissibility of systemic amyloidosis by a prion-like mechanism , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[227]  H. Morita,et al.  Long-term follow-up of systemic reactive AA amyloidosis secondary to rheumatoid arthritis: successful treatment with intermediate-dose corticosteroid. , 2002, Internal medicine.

[228]  B. Olofsson,et al.  Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. , 2002, Transplantation.

[229]  E. Check.  Nerve inflammation halts trial for Alzheimer's drug , 2002, Nature.

[230]  John Q. Trojanowski,et al.  Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.

[231]  M. Sousa,et al.  Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. , 2001, The American journal of pathology.

[232]  J. Kelly,et al.  Trans-Suppression of Misfolding in an Amyloid Disease , 2001, Science.

[233]  J. Hamilton,et al.  Transthyretin: a review from a structural perspective , 2001, Cellular and Molecular Life Sciences CMLS.

[234]  H. M. Petrassi,et al.  An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. , 2001, Biochemistry.

[235]  J. Kelly,et al.  Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins , 2001, Protein science : a publication of the Protein Society.

[236]  L. Lovat,et al.  Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein , 2001, The Lancet.

[237]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[238]  B. Ericzon,et al.  Results from the familial amyloidotic polyneuropathy world transplant registry. , 2001, Transplantation proceedings.

[239]  H. Lehrach,et al.  Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. , 2001, Human molecular genetics.

[240]  T. Saido,et al.  Metabolic Regulation of Brain Aβ by Neprilysin , 2001, Science.

[241]  J. Kelly,et al.  Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[242]  Brian J. Bacskai,et al.  Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy , 2001, Nature Medicine.

[243]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[244]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[245]  A. Olofsson,et al.  A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. , 2000, Journal of molecular biology.

[246]  S. Lindquist,et al.  Nucleated conformational conversion and the replication of conformational information by a prion determinant. , 2000, Science.

[247]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[248]  E. Wanker,et al.  Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[249]  Bernd Bukau,et al.  Multistep mechanism of substrate binding determines chaperone activity of Hsp70 , 2000, Nature Structural Biology.

[250]  A. Roher,et al.  Evidence for Seeding of β-Amyloid by Intracerebral Infusion of Alzheimer Brain Extracts in β-Amyloid Precursor Protein-Transgenic Mice , 2000, The Journal of Neuroscience.

[251]  James C. Sacchettini,et al.  Rational design of potent human transthyretin amyloid disease inhibitors , 2000, Nature Structural Biology.

[252]  M. Saraiva,et al.  Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: Ocular synthesis of mutant transthyretin , 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[253]  H. Paulson,et al.  Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70 , 1999, Nature Genetics.

[254]  C. Wurth,et al.  The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. , 1999, Biochemistry.

[255]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[256]  William J. Ray,et al.  A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain , 1999, Nature.

[257]  F. Ferrone,et al.  Analysis of protein aggregation kinetics. , 1999, Methods in enzymology.

[258]  R. Morimoto,et al.  Regulation of the Heat Shock Transcriptional Response: Cross Talk between a Family of Heat Shock Factors, Molecular Chaperones, and Negative Regulators the Heat Shock Factor Family: Redundancy and Specialization , 2022 .

[259]  Scott A. Peterson,et al.  Discovering transthyretin amyloid fibril inhibitors by limited screening. , 1998, Bioorganic & medicinal chemistry.

[260]  M. Pepys,et al.  Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation , 1998, European Journal of Nuclear Medicine.

[261]  P. Westermark,et al.  Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[262]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[263]  Christopher M. Dobson,et al.  Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis , 1997, Nature.

[264]  P. Lansbury,et al.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. , 1997, Annual review of biochemistry.

[265]  Scott A. Peterson,et al.  Inhibiting transthyretin amyloid fibril formation via protein stabilization. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[266]  Allan I. Levey,et al.  Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo , 1996, Neuron.

[267]  J. Kelly,et al.  The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. , 1996, Biochemistry.

[268]  H. Budka,et al.  Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G) , 1996, The American journal of pathology.

[269]  D. Selkoe,et al.  The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway , 1995, Nature Medicine.

[270]  A Coda,et al.  Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. , 1995, Science.

[271]  J R Ghilardi,et al.  1H NMR of A beta amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence. , 1995, Biochemistry.

[272]  Leon D. Segal,et al.  Functions , 1995 .

[273]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[274]  Maria João,et al.  Transthyretin mutations in health and disease , 1995, Human mutation.

[275]  L. Amaducci,et al.  Aging as a major risk for degenerative diseases of the central nervous system: Editorial commentary , 1994, Current opinion in neurology.

[276]  M. Hurle,et al.  A role for destabilizing amino acid replacements in light-chain amyloidosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[277]  J Carter,et al.  Molecular Pathology of Alzheimer's Disease , 2013 .

[278]  R. Kisilevsky,et al.  During AA amyloidogenesis is proteolytic attack on serum amyloid A a pre- or post- fibrillogenic event? , 1994 .

[279]  R J Fletterick,et al.  Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[280]  P. Roller,et al.  Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein. , 1993, The Journal of biological chemistry.

[281]  P. Lansbury,et al.  Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.

[282]  S. Prusiner,et al.  THE SITES OF PrPSc DEPOSITION IN THE BRAIN ARE PRION STRAIN SPECIFIC , 1993 .

[283]  B. Wallin,et al.  Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis , 1993, The Lancet.

[284]  T. Coelho,et al.  A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR MET 30 and TTR MET 119 , 1993 .

[285]  R. Carp,et al.  Brain regional distribution of prion protein PrP27-30 in mice stereotaxically microinjected with different strains of scrapie. , 1993, The Journal of infectious diseases.

[286]  J. Kelly,et al.  Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. , 1992, Biochemistry.

[287]  C. Glabe,et al.  Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[288]  G. Drewes,et al.  Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer‐like state. , 1992, The EMBO journal.

[289]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[290]  R. Marsh,et al.  Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent , 1992, Journal of virology.

[291]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[292]  G. Holmgren,et al.  Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP‐met30) , 1991, Clinical genetics.

[293]  K. Fischbeck,et al.  Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy , 1991, Nature.

[294]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[295]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[296]  K. Shimada,et al.  [Familial amyloidotic polyneuropathy]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[297]  K. Sletten,et al.  Fibril in senile systemic amyloidosis is derived from normal transthyretin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[298]  G. Glenner,et al.  Alzheimerʼs disease and Downʼs syndrome: sharing of a unique cerebrovascular amyloid fibril protein , 1988 .

[299]  D. Selkoe,et al.  Microtubule-associated protein tau (? ) is a major antigenic component of paired helical filaments in Alzheimer disease , 1987 .

[300]  D. Selkoe,et al.  Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[301]  J. Hofrichter,et al.  Kinetics of sickle hemoglobin polymerization. II. A double nucleation mechanism. , 1985, Journal of molecular biology.

[302]  E. Craig,et al.  The Heat Shock Respons , 1985 .

[303]  E. Craig,et al.  The heat shock response. , 1985, CRC critical reviews in biochemistry.

[304]  S J Oatley,et al.  Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. , 1977, Journal of molecular biology.

[305]  A. Baer.  The genetic perspective , 1977 .

[306]  J. Hofrichter,et al.  Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[307]  G. Glenner,et al.  Amyloid Fibril Proteins: Proof of Homology with Immunoglobulin Light Chains by Sequence Analyses , 1971, Science.

[308]  M. Skinner,et al.  Characterization of the Amyloid Fibril as a Cross-β Protein∗ , 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[309]  C ANDRADE,et al.  A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. , 1952, Brain : a journal of neurology.